COVID-19. COVID-19 disease
Conditions
Interventions
Intervention 1: Intervention group 1:In addition to standard treatment (400 mg of hydroxychloroquine) in the amount of 400 mg of raltagravir twice a day for 10 days and will receive tablets. Intervent
Sponsors
Jahrom University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: confirmed diagnosis of COVID19 with RT-PCR hospitalized patients
Exclusion criteria
Exclusion criteria: Patients with severe dyspnea require mechanical ventilation or hospitalization in intensive care units and patients with treatment-resistant hypoxemia or those with severe underlying disease Pregnancy or breastfeeding Drug allergy Patient dissatisfaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In this study, Sequential Organ Failure Assessment (SOFA) will be used to assess the severity of the disease. In this criterion, respiratory systems (PaO2 / Fio2 measurement), coagulation (platelet count), liver (bilirubin level), cardiovascular (hypotension), central nervous system (CNS) and kidney (creatinine level or urinary tract) Will be reviewed. Each parameter is graded on a 5-point Likert scale (score between zero and 4). The total score is between zero and 28. Higher scores indicate a worse patient condition. Timepoint: Before and after the intervention. Method of measurement: The data will be collected using the information in the patient's file. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Rahim Raoufi
Jahrom University of Medical Sciences
Outcome results
None listed